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Is Cystatin C Useful for the Detection and the
Estimation of Low Glomerular Filtration Rate in Heart
Transplant Patients?
Pierre Delanaye,1,6 Eric Nellessen,2 Etienne Cavalier,3 Gise`le Depas,4 Ste´phanie Grosch,1
Jean-Olivier Defraigne,5 Jean-Paul Chapelle,3 Jean-Marie Krzesinski,1 and Patrizio Lancellotti2
Although previously studied in patients with chronic kidney disease, there is less data for the use of cystatin C and
cystatin C–based formulas in heart transplant recipients. The ability of creatinine and cystatin C to detect renal failure
(glomerular filtration rate [GFR] below 60 mL/min/1.73 m2) in heart transplant patients has been compared. The
accuracy and precision of a creatinine-based formula (Modification ofDiet in RenalDisease [MDRD]) versus a cystatin
C-based formula (Rule’s formula) to estimate GFR have also been studied. GFR was measured using the 51 Cr-
ethylenediamine tetraacetic acid tracer in 27 patients. There was no significant difference between GFR and the recip-
rocal of creatinine or cystatinC. Receiver operating characteristic curves for cystatinC and creatininewere similar. Both
formulas were well correlated with the GFR. The bias of the cystatin C-based was significantly better than one of the
MDRD formula, but the standard deviation appeared better for the MDRD formula (bias of 3.9 mL/min/1.73 m2
versus 12 mL/min/1.73 m2 and SD of 8.5 versus 11.6, respectively). Plasma cystatin C has no clear advantage over
serum creatinine to detect renal failure in heart transplanted patients.
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Chronic renal failure is a common complication in hearttransplant patients (1–3). Serum creatinine is the classical
marker used to detect renal failure. However, this marker has
clear limitations because of serum concentration variations ac-
cording tomusclemass and tubular secretion (3–5). Plasma cys-
tatin C is presented as a newmarker of glomerular filtration rate
(GFR) (6, 7). Notably, its plasma concentration has been shown
to be independent of the muscular mass (8). Even if it remains
controversial, several authors have described the superiority of
plasma cystatin C over serum creatinine to detect renal failure
(9–11). The goal of this study was to compare the interest of
creatinineandcystatinC todetect renal failure inapopulationof
heart transplant patients. Moreover, we have recently shown in
the same cohort of patients that theModification of Diet in Re-
nal Disease (MDRD) formula was the best of the creatinine-
based formulae to estimateGFR (12).Here, theMDRD formula
was compared with a new cystatin C-based formula for the esti-
mation of GFR (13).
The study population consisted of 27 white patients.
The exclusion criteria were age 15 years and a body mass
index35 kg/m2. The referencemethod forGFRmeasurement
was based on plasma clearance of 51Cr-ethylenediamine tet-
raacetic acid (EDTA) (14). Results were corrected by body
surface area (15). Serum creatinine was measured with the
kinetic rate-blanked compensated creatinine Jaffe´ method on
Modular (RocheDiagnostics; reference values:1.21mg/dL for
themen and1.02mg/dL for the women) (16). Plasma cysta-
tin C was measured by a particle-enhanced nephelometric
immunoassay (Dade Behring) (17). A value of cystatin C 1
mg/Lmaybe considered as normal in the general population (18).




Rule et al. have recently elaborated a specific cystatin
C-based formula for transplanted patients. Two hundred and
six transplanted patients have been observed in this study,
including 30 heart transplant patients (13).
GFRCC76.6cystatin
1.16
The plasma markers used to detect renal failure were
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compared by correlation analysis and the receiver operating
characteristic curves methods. The area under the curves was
calculated to detect a GFR below 60 mL/min/1.73 m2. A co-
efficient of correlation between the estimated GFR (by creat-
inine or cystatin-based formula) and the measured GFR was
calculated. A Bland and Altman analysis was performed. The
bias was defined as the mean of the differences between the
predicted and measured GFR. The standard deviations of
the mean differences between measured and estimated GFR
reflect the precision of the estimation. Formulae accuracywas
determined by the percentage of the estimated GFR within
30% of the measured GFR. Statistical analyses were performed
usingMedCalc (MedCalc Software, Mariakerke, Belgium).
GFR measurement was performed in 27 white heart
transplant patients (five women, 22 men). The clinical char-
acteristics of the population were described previously (12).
All patients had normal thyroid function. Among these 27
patients, 24 (89%) had aGFR lower than 60mL/min/1.73m2.
After this first determination, the GFR was measured
again at least 10months later in 22 patients. ThemeanGFR10
months later remained stable for those 22 patients. All isoto-
pic GFR measurements (49) were pooled and their mean
value was 3915 mL/min/1.73 m2. A significant correlation
between theGFR and the reciprocal of creatinine and cystatin
C (r0.75, P0.0001 and r0.66, P0.0001, respectively)
was found. There was no difference between these correla-
tions (Fig. 1).
To detect a GFR less than 60 mL/min/1.73 m2, the area
under the curve was 0.86 for the creatinine and 0.83 for the
cystatin C. The difference was not significant (Fig. 2). The
creatinine value that gave the best sensitivity-specificity was
1.32mg/dL (sensitivity of 72.7%, specificity of 100%). For the
cystatin C, the value was 1.51 mg/L (sensitivity of 81.1%,
specificity of 83.3%).
Both MDRD and Rule formulae were moderately cor-
related with GFR (r0.83 and r0.66, respectively, no statis-
tical difference). The coefficients of determinations (r2) were
also relatively low (0.69 and 0.44, respectively). The Bland
and Altman analyses are given in Figure 3. The precision of
theMDRD formula is linked to the SDof themeandifference.
The precision of the MDRD formula was statistically better
than the Rule formula (SD 8.5 versus 11.6, P0.033). Never-
theless, the bias of the Rule cystatin-based formula was
smaller than in the MDRD formula (3.9 mL/min versus
12 mL/min, respectively, P0.0002). The GFR estimated
with the MDRD formula was found within 30% measured
GFR in 43% cases, whereas the percentages were 67% for the
GFR estimated by the cystatin-based formula (P0.029).
Given the high prevalence of C-reactive protein, the
detection of reduced GFR is of great importance in the heart
transplant population (2, 3). In this study, plasma cystatin C
had no clear advantage over serum creatinine to detect renal
failure. Nevertheless, for the estimation of GFR, the cystatin
C-based equation could have some advantages over the
MDRD equation.
Serum creatinine has a poor sensitivity to detect renal
failure in the general population (5, 19). This marker may be
even less accurate in heart transplant recipients because this
population has a reduced muscular mass, notably because of
chronic therapy by corticosteroids (4, 20, 21). Regarding
transplant populations, Tomlanovich et al. have also shown
some degree of creatinine tubular hypersecretion, dependent
on cyclosporine therapy (4). If the reference values of creati-
nine with our Jaffe´ method are considered, 63.6% of our pa-
tients with normal creatinine values had a GFR less than 60
FIGURE 1. Correlations between measured GFR (by
51Cr-EDTA plasmatic clearance) and the reciprocal of cre-
atinine (A) and the reciprocal of cystatin C (B). (A) r0.75
P0.0001. (B) r0.66 P0.0001.
FIGURE 2. Receiver operating characteristic curves for
cystatin C and creatinine (cutoff value for GFR60 mL/min/
1.73 m2).
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mL/min/1.73 m2. Nevertheless, the specificity of the serum
creatinine was excellent.
The ability for plasma cystatin C to detect renal failure
was not better than for serum creatinine. This can be ex-
plained by the lack of specificity of the cystatin C. All patients,
even those with a GFR greater than 60 mL/min/1.73 m2 had
high cystatinC levels. Two arguments are proposed to explain
these results. Firstly, some factors can interfere with cystatin
C concentrations (dysthyroidism, smoking, weight) (22, 23).
Maybe more important in the context of transplantation,
some authors have suggested that corticoids can induce an
increase of cystatin C concentration independently of any
GFR changes (24, 25). This fact is still debated (26). However,
in our patients, the cystatin C value that gives the best sensi-
tivity-specificity ratewas 1.51mg/dL,which is higher than the
maximal normal value obtained in a normal population (18).
The second explanation that may explain the lack of superi-
ority of cystatin C may be linked to the range of GFR in our
population. The majority of our patients had a GFR less than
60 mL/min/1.73 m2, although cystatin C is thought to be
superior especially to detect a GFR between 60 and 80 mL/
min/1.73 m2 (11, 27).
For the estimation of GFR, the Kidney/Disease Out-
comes Quality Initiative (K/DOQI) guidelines recommend
the use of creatinine-based formula and, among these, favor
to the MDRD formula (19). However, we have recently
shown that MDRD precision and accuracy are less in heart
transplanted patients than in other populations (12). Re-
cently, Rule et al. have elaborated a new cystatin-based for-
mula from a large transplanted population.With the formula
of Rule et al., the bias and the accuracy of the cystatin C-
formula were significantly better than those of the MDRD.
However, the precision reflected by the standard deviation
and the correlation with GFR of the Rule formula was poor.
Why this lack of precision? First, as we have already shown,
cystatin C concentrations may be influenced by corticoids
therapy. Our population was not homogeneous in term of
corticotherapy, as 27% of our patients were corticoid-free.
Moreover, the percentage of patients not treated by corticoids
in the Rule study was not given. Secondly, the lack of preci-
sion of the cystatin C-based equations may be linked to the
different assays for the cystatin C measurement and varied
calibrations. Indeed, as it is the case with the creatinine, lack of
precision or lack of calibration in themeasurement of cystatinC
willhavegreat repercussionson theprecisionof cystatinC-based
formulae (27–29). As for creatinine (30), harmonization and
better precision are thus needed for themeasurement of plasma
cystatin C.
There are limitations to our study. Our sample was
rather small. However, as we have already shown (12), the
GFR range of our population appeared quite representative of
theGFR range in the global heart transplanted population.Of
importance, the conclusions of our study remained similar
when statistics were limited to the first 27 patients and to the
22 patients who had had two GFR measurements (data not
shown).
Plasma cystatin C was not better than serum creatinine
for detecting renal failure in a representative population of
heart transplant patients. Nevertheless, if the serum creati-
nine of a heart transplant patient was abnormally high, one
can conclude that this patient had a GFR less than 60 mL/
min/1.73 m2. In fact, with our creatinine assay, a value more
than 1.32 mg/dL had a specificity of 100% to detect renal
failure (and a sensitivity of 72.7%).With our cystatin C assay,
a value more than 1.01 mg/L had a sensitivity of 100% but a
very low specificity. In other words, if the plasma cystatin C
was in the normal range, then the patient had aGFR of at least
60 mL/min/1.73 m2. The bias and the accuracy (but not the
precision) of the cystatin C-based formula were better than
those of the MDRD formula. These preliminary data have to
be confirmed on a larger sample. If a precise GFR is needed in
clinical practice or studies with heart transplant patients, we
do recommend the use of a reference method measurement.
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